Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
IPO Year:
Exchange: NYSE
Website: lilly.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2026 | $1250.00 | Outperform | RBC Capital Mkts |
| 2/20/2026 | $1350.00 | Overweight | Barclays |
| 1/7/2026 | $1250.00 | Buy | UBS |
| 12/16/2025 | $1230.00 | Neutral → Buy | Daiwa Securities |
| 12/15/2025 | $951.00 → $1145.00 | Buy | Goldman |
| 12/15/2025 | $1286.00 → $1268.00 | Buy | BofA Securities |
| 11/13/2025 | $1165.00 | Sector Outperform | Scotiabank |
| 11/10/2025 | $1104.00 | Market Perform → Outperform | Leerink Partners |
| 10/20/2025 | $840.00 → $930.00 | Outperform | BMO Capital Markets |
| 10/14/2025 | Hold → Buy | Erste Group |
10-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
144 - ELI LILLY & Co (0000059478) (Subject)
10-Q - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
FWP - ELI LILLY & Co (0000059478) (Subject)
10-Q - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
For Immediate Release: September 23, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “FDA Issues New Guidance to Help Facilitate Availability of Naloxone to Prevent Opioid Overdoses and Reduce Death,” by Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Center f
For Immediate Release: June 13, 2022 Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific locati
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4/A - ELI LILLY & Co (0000059478) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00
Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00
UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00
Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00
Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously
BofA Securities reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,268.00 from $1,286.00 previously
Scotiabank initiated coverage of Eli Lilly with a rating of Sector Outperform and set a new price target of $1,165.00
Leerink Partners upgraded Eli Lilly from Market Perform to Outperform and set a new price target of $1,104.00
BMO Capital Markets reiterated coverage of Eli Lilly with a rating of Outperform and set a new price target of $930.00 from $840.00 previously
Erste Group upgraded Eli Lilly from Hold to Buy
Fastest customizable press release news feed in the world
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeksThe study is the first and largest of its kind specifically designed to evaluate children and adolescents with severe AA, a disease that has devastating social and emotional impactLilly has also submitted Olumiant in the U.S. for approval to treat severe AA in adolescents, with a decision expected in the second half of 2026INDIANAPOLIS, Feb. 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Produ
The chondrosarcoma market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies such as Ozekibart (INBRX-109) (Inhibrx Biosciences), TIBSOVO (ivosidenib) (Servier), LY3410738 (Eli Lilly), and others, and global healthcare spending, reports DelveInsight.LAS VEGAS, Feb. 26, 2026 /PRNewswire/ -- Recently published chondrosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, chondrosarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight lossLilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight lossIn a key secondary endpoint, patients taking Taltz and Zepbound were 40% more likely to achieve PASI 100 compared to those taking Taltz alone (40.6% of patients vs. 29.0%, p<0.05)Taltz is the first and only psoriatic disease biologic with data from two trials supporting a potential comprehensive treatment approach alongside an incretin therapy for obesity INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the landmark TOGETHER-P
The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036,
Milestone achieved in Scribe and Lilly's ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases Achievement validates Scribe's technologies and strengthens momentum across its genetic medicine portfolio, including its internal pipeline advances for cardiovascular and metabolic disease Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced the achievement of a second success milestone for one of the targets in its collaboration with Eli
The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,
Live finance-specific insights
Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in
INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into h
INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. Regulatory progre
INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new d
INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into heal
Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi
INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into hea
INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis
INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries
Live Leadership Updates
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell
INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve
INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b
Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Marschall S. Runge, M.D., Ph.D. is retiring from his role as an independent director of Lilly's board of directors effective Aug. 31, 2024. Dr. Runge has served on Lilly's board since 2013, including as a member of the board's Science and Technology Committee and Ethics and Compliance Committee. He is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan and dean of the Medical School, and he plans to retire on June 30, 2025. Following retirement from these leadership roles, Dr. Runge will remain on the Medical School faculty as a prof
INDIANAPOLIS, June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year. "As we expand global capacity to meet demand and support pipeline growth, we remain committed to ensuring our medicines are produced to the highest quality standards," said David A. Ricks, Lilly's chair and CEO. "With more than 25 years of experience and a proven
INDIANAPOLIS, May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer. "Throughout his distinguished career, Alonzo has been a steadfast advocate for our company, providing strategic guidance to our global product development teams and major geographies worldwide," said David A. Ricks, Lilly's
This live feed shows all institutional transactions in real time.
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)